Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma

M Stiefel1, T Reiss, M S Staege

  • 1Department of Pediatric, Hematology-Oncology, Martin-Luther University Halle-Wittenberg, Halle, Germany.

Pediatric Blood & Cancer
|December 8, 2005
PubMed

Insights

Cerebral aspergillosis, a rare brain-only infection, poses a poor prognosis. Concentration-controlled voriconazole therapy achieved a complete response in an 11-year-old boy with Aspergillus fumigatus brain abscess.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive aspergillosis is a growing concern in immunocompromised individuals.
  • Cerebral aspergillosis, though rare as an isolated infection, presents a significant challenge with poor outcomes.
  • Medulloblastoma treatment can lead to complications like localized fungal infections.

Observation:

  • An 11-year-old boy with medulloblastoma developed abscess-like structures post-surgery and radio-chemotherapy.
  • Histology and culture confirmed localized Aspergillus fumigatus infection.
  • Initial treatment with amphotericin B failed, and voriconazole showed partial response.

Findings:

  • Switching to oral voriconazole led to abscess regrowth.
  • Adjusting voriconazole dosage to achieve therapeutic cerebrospinal fluid (CSF) and plasma concentrations was critical.
  • Concentration-controlled voriconazole therapy over 18 months resulted in complete resolution of the Aspergillus fumigatus abscess.

Implications:

  • Optimizing antifungal drug concentrations in CSF is crucial for treating cerebral aspergillosis.
  • Concentration-controlled therapy can be effective for refractory cases of invasive fungal brain infections.
  • This case highlights a successful strategy for managing localized Aspergillus infections in pediatric neuro-oncology patients.